Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06225310 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06225310 · ClinicalTrials.gov record · last posted 2025-01-16

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Study acronym: KPT-IST-391
StatusRecruiting
PhasePhase 1
Started2024-08-06
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2024-01-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-01-14
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06225310
Lead Sponsor Oncotherapeutics
Conditions Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Enrollment 30 participants
Start Date 2024-08-06
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-16